resTORbio to Present at Upcoming Investor Conferences in November
07 nov. 2018 08h00 HE
|
resTORbio, Inc.
BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio Appoints Michael Grissinger to its Board of Directors
06 nov. 2018 08h00 HE
|
resTORbio, Inc.
- Brings extensive business development and licensing experience to resTORbio’s Board - BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical...
resTORbio Announces Additional RTB101 Phase 2b Data Demonstrating Decreased Incidence of Laboratory-Confirmed RTIs with Severe Symptoms, Total Infections and UTIs
16 oct. 2018 07h12 HE
|
resTORbio, Inc.
RTB101 10 mg once daily decreased incidence of laboratory-confirmed respiratory tract infections (RTIs) with severe symptoms by 52.1% vs. placebo (p=0.034) In addition to decreasing the incidence of...
resTORbio to Present at 2018 Cantor Fitzgerald Global Healthcare Conference
24 sept. 2018 08h00 HE
|
resTORbio, Inc.
BOSTON, Sept. 24, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio Appoints Meredith Manning as Chief Commercial Officer
18 sept. 2018 08h00 HE
|
resTORbio, Inc.
BOSTON, Sept. 18, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq:TORC), a clinical biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio to Present at Wells Fargo 2018 Healthcare Conference
29 août 2018 08h00 HE
|
resTORbio, Inc.
BOSTON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio Appoints Jeffrey Chodakewitz, M.D., to its Board of Directors
15 août 2018 08h00 HE
|
resTORbio, Inc.
BOSTON, Aug. 15, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio Reports Second Quarter 2018 Financial Results
09 août 2018 08h00 HE
|
resTORbio, Inc.
Phase 2b results identify dose and patient population for pivotal program with RTB101 Initiation of pivotal program with RTB101 expected in the first half of 2019 BOSTON, Aug. 09, 2018 (GLOBE...
resTORbio to Present at the Canaccord Genuity 38th Annual Growth Conference
30 juil. 2018 07h00 HE
|
resTORbio, Inc.
BOSTON, July 30, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio Announces Positive Topline Results in Phase 2b Trial of RTB101
25 juil. 2018 07h00 HE
|
resTORbio, Inc.
-- Statistically significant and clinically meaningful 30.6% reduction in the percentage of patients with one or more laboratory-confirmed respiratory tract infections (RTIs), the primary endpoint of...